A Phase II Evaluation of Weekly Paclitaxel Plus Carboplatin in Advanced Urothelial Cancer

References

• American Cancer Society. What are the Key Statistics for Bladder Cancer?, http://www.cancer.org, accessed July 05, 2002
   Google Scholar
• Greenlee R. T., Murray T., Bolden S., Wingo P. A. Cancer statistics, 2000. CA. Can. J. Clin. 2000; 50(1)7–33
   PubMed Web of Science ®Google Scholar
• Sternberg C. N., Yagoda A., Scher H. I., Watson R. C., Geller N., Herr H. W., Morse M. J., Sogani P. C., Vaughan E. D., Bander N. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer 1989; 64(12)2448–2458, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Logothetis C. J., Dexeus F., Finn L., Sella A., Amato R. J., Ayala A. G., Kilbourn R. G. A prospective randomized trial comparing CISCA to MVAC chemotherapy in advanced metastatic urothelial tumors. J. Clin. Oncol. 1990; 8(6)1050–1055, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• LoehrerSr P. J., Einhorn L. H., Elson P. J., Crawford E. D., Kuebler P., Tannock I., Raghavan D., Stuart-Harris R., Sarosdy M. F., Lowe B. A. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992; 10(7)1066–1073
   PubMed Web of Science ®Google Scholar
• Von der Maase H., Hansen S. W., Roberts J. T., Dogliotti L., Oliver T., Moore M. J., Bodrogi I., Albers P., Knuth A., Lippert C. M., Kerbrat P., Sanchez Rovira P., Wersall P., Cleall S. P., Roychowdhury D. F., Tomlin I., Visseren-Grul C. M., Conte P. F. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large randomized, multinational, multicenter phase III study. J. Clin. Oncol. 2000; 18(17)3068–3077, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Roth B. J., Dreicer R., Einhorn L. E., Neuberg D., Johnson D. H., Smith J. L., Hudes G. R., Schultz S. M., Loehrer P. J. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 1994; 12(11)2264–2270, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Dreicer R., Manola J., Roth B. J., Cohen M. B., Hatfield A. K., Wilding G. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 2000; 18(5)1058–1061, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Tu S. M., Hossan E., Amato R., Kilbourn R., Logothetis C. J. Paclitaxel, cisplatin, and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. J. Urol. 1995; 154(5)1719–1722, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bajorin D. F., McCaffrey J. A., Dodd P. M., Hilton S., Mazumdar M., Kelly W. K., Herr H., Scher H. I., Icasiano E., Higgins G. Ifosfamide, Paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules. Cancer 2000; 88(7)1671–1678, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Langer C. J., Leighton J. C., Comis R. L., O'Dwyer J. P., McAleer C. A., Bonjo C. A., Engstron P. F., Lifein S., Ozols R. F. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: phase II toxicity, response, and survival analysis. J. Clin. Oncol. 1995; 13(8)1860–1870, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Natale R. B. Preliminary results of a phase I/II clinical trial of paclitaxel and carboplatin in non-small cell lung cancer. Semin. Oncol. 1996; 23(5 suppl 12)2–6, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Vaughn D. J., Malkowicz S. B., Zoltick B., Mick R., Ramchandani P., Holroyde C., Armstead B., Fox K., Wein A. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J. Clin. Oncol. 1998; 16(1)255–260, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Redman B. G., Smith D. C., Flaherty L., Du W., Hussain M. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J. Clin. Oncol. 1998; 16(5)1844–1848, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Small E. J., Lew D., Redman B. G., Petrylak D. P., Hammond N., Gross H. M., Eastham J. A., Crawford E. D. Southwest oncology group study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. J. Clin. Oncol. 2000; 18(13)2537–2544, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Ukena D., Leutz M., Schroder R., Sybrecht G. W. Intensified treatment of stage IV non-small cell lung cancer (NSCLC): weekly chemotherapy with paclitaxel and carboplatin. Lung Cancer 1997; 18(1)34, Abstract 122[CROSSREF]
   Google Scholar
• Simon R. Optimal two-stage designs for phase II clinical trials. Control. Clin. Trials 1989; 10(1)1–10, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958; 53(282)457–481, [CSA]
   Web of Science ®Google Scholar
• Meluch A. A., Burris H. S., Greco F. A., Hainsworth J. D. Gemcitabine and paclitaxel combination therapy in transitional cell carcinoma of the urothelium. Eur. J. Cancer 2000; 36(suppl 2)30–33, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Bajorin D. F., Dodd P. M., Mazumdar M., Fazzari M., McCaffrey J. A., Scher H. I., Herr H., Higgins G., Boyle M. G. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J. Clin. Oncol. 1999; 17(10)3173–3181, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Dodd P. M., McCaffrey J. A., Hilton S., Mazumdar M., Herr H., Kelly W. K., Icasiano E., Boyle M. G., Bajorin D. F. Phase I evaluation of sequential doxorubicin plus gemcitabine then ifosfamide plus paclitaxel plus cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract. J. Clin. Oncol. 2000; 18(4)840–846, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Witte R. S., Elson P., Bono B., Knop R., Richardson R. R., Dreicer R., Loeher P. J. Eastern cooperative oncology group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J. Clin. Oncol. 1997; 15(2)589–593, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Lorusso V., Pollera C. F., Antimi M., Luporini G., Gridelli C., Frassinetti G. L., Oliva C., Pacini M., DeLena M. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Eur. J Cancer 1998; 34(8)1208–1212, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar